sunpharma ranbaxy acquisition
Post on 15-Jul-2015
1.043 Views
Preview:
TRANSCRIPT
Introduction: Pharmacy Sector The pharmaceutical industry develops, produces,
and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic or brand medications and medical devices.
The Pharmaceutical industry has grown from mere US$o.3 billion turnover in 1980 to 15 billion in 2012-2013.
Globally, India ranks 3rd in terms of volume of production(10 per cent of global share) and 14th
largest by value. (1.5 per cent of global share)
The reason for lower value share is the lowest cost of drugs in India ranging from 5 to 50 per cent less as compared to developed countries.
Sun Pharma Established in 1983, listed since 1994 and
headquartered in India, Sun Pharma is an international, integrated, specialty pharmaceutical company.
In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology.
The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms and APIs.
The 2014 acquisition of Ranbaxy will make the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest speciality generic company globally.
Ranbaxy Ranbaxy Laboratories Limited is an Indian
multinational pharmaceutical company that was incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in 2008.
Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries.
In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award.
Acquisition
Apr 06, 2014:To create world’s 5th largest
specialty generic pharma company
No. 1 pharma company in India with leadership
position in 13 specialty segments
No. 1 Indian pharma company in the US
Daiichi Sankyo to become the second largest
shareholder in Sun Pharma
Why Ranbaxy?
Ranbaxy has got a lot of ANDA's (Abbreviated New Drug Application) approved for marketing in USA. Their problem is to find an API plant because main source of API was from Toansa. If Sun Pharma fills this gap, Ranbaxy can begin its export to the USA. So, Sun Pharma has got into this deal at the right time and deal has an upside for all the shareholders.
Sun Pharma’s managing director Dilip Shanghvihas acquired a reputation for acquiring companies in trouble at a good price, and then turning around their operations
Why Daichi sold Ranbaxy ?
Daiichi faced criticism after Ranbaxy’s plants
came under the US Food and Drug
Administration’s (FDA’s)
Ranbaxy’s inability to overcome its FDA-related
problems has put pressure on its promoters.
With Sun Pharma acquiring Ranbaxy, Daiichi is
relieved of the burden of managing Ranbaxy’s
problems. It will hold a 9% stake in Sun Pharma,
as a result of its current stake in Ranbaxy.
Valuation Sun Pharmaceutical Industries fully acquired
troubled Ranbaxy Laboratories, in an all-stock transaction with a total equity value of USD 3.2 billion.
Under these agreements, Ranbaxy shareholders received 0.8 share of Sun Pharma for each share of Ranbaxy.
The deal lead to 16.4% dilution in the equity capital of Sun Pharma. This is because its total equity value is $3.2 billion and the deal size is $4 billion
The combined entity’s revenues were USD 4.2 billion with EBITDA of USD 1.2 billion for the twelve month period ended December 31, 2013.
Transaction Highlights
Sun Pharma to acquire Ranbaxy
Ranbaxy shareholders to get 0.8 shares of Sun
Pharma stock for every share of Ranbaxy
Deal size approximately US$ 4 billion.
Daiichi Sankyo to become the second largest
shareholder in SunPharma. Strategic business
relationship to continue with SunPharma Voting
Agreements
Daiichi Sankyo to vote in favor of transaction
(~63.5% ownership) SunPharma promoters to
vote in favor of transaction (~63.7% ownership)
Indemnity:
In connection with the transaction, Daiichi
Sankyo has agreed to indemnify SunPharma and
Ranbaxy for, among other things, certain costs
and expenses that may arise from the recent
subpoena which Ranbaxy has received from the
United States Attorney for the Toansa facility.
Conditions to close:
Requisite approval of Sun Pharma and Ranbaxy
shareholders
Approval of the Indian Central Government and
various other regulatory bodies
Advisors Citi and Evercore were acting as financial
advisors for the transaction to Sun Pharma. Sun Pharma’s legal advisors are Shearman & Sterling LLP, Crawford Bayley & Co and S. H. Bathiya & Associates.
Ranbaxy’s financial advisor for the transaction is ICICI Securities and its legal advisors are Luthra& Luthra Law Offices and Amarchand & Mangaldas & Suresh A Shroff & Co.
Daiichi Sankyo’s financial advisor for the transaction is Goldman Sachs and its legal advisors are Davis Polk & Wardwell LLP and Amarchand & Mangaldas & Suresh A Shroff & Co.
Problems to be faced by SunPharma
The deal, has also seen Sun assume $800 million
of debt on Ranbaxy’s books, needs shareholder
and regulatory clearances.
Ranbaxy’s all four plants have been banned by
the USDFA for violations of manufacturing norms.
In 2013, the company agreed to pay USD 500
million fine after pleading guilty to felony charges
over manufacturing and distribution of adulterated
drugs in the US.
Conclusion That was the right time for Sun Pharma to buy
Ranbaxy. Ranbaxy's problem with US Food and Drug Administration (FDA) cannot get more intense than they are already, things can only improve from now onwards. There will be tremendous synergy between the two companies when they are merged as single entity. It will be the largest Indian generic company and the fifth largest in the world.
The merger will see Sun Pharma’s revenue jump by a healthy 40% but its operating profit will rise by a meagre 7.5%, based on pro forma 2013 financials. Its operating profit margin will decline from 44.1% to 29.2%. Thus, the merger will have a negative effect on its performance in the near term.
Bibliography
http://www.rediff.com/business/report/benefit-of-
ranbaxy-deal-to-accrue-in-few-years-sun-
pharma/20140929.htm
http://businesstoday.intoday.in/story/ranbaxy-
acquisition-good-for-sun-pharma-shareholders-
experts/1/205526.html
www.sunpharma.com
www.ranbaxy.com
www.moneycontrol.com
top related